目的观察氟达拉滨联合环磷酰胺（FC）方案治疗慢性淋巴细胞白血病的临床疗效及安全性。方法回顾性分析15例应用氟达拉滨联合环磷酰胺方案治疗的慢性淋巴细胞白血病患者临床资料，以评估其近期疗效，并观察记录药物不良反应。结果15例患者中完全缓解6例（占40%）、部分缓解4例（占26.7%）、无效5例（占33.3%），总有效率为66.7%；治疗期间主要不良反应为骨髓抑制和感染。结论应用氟达拉滨联合环磷酰胺方案治疗慢性淋巴细胞白血病有显著的临床疗效，因其副作用少且安全性好，是目前治疗慢性淋巴细胞白血病首选方案。% Objective Fluoride dara marina combined cyclophosphamide (FC) scheme, treatment the clinical curative effect and safety of chronic lymphocytic leukemia. Methods Retrospective analysis of 15 cases of application of fluorine dara marina combined therapy with cyclophosphamide scheme of chronic lymphocytic leukemia patients clinical data, to evaluate the recent efficacy, record adverse drug reactions were observed. Asaresult 15 patients in complete remission in 6 (40%), partial in 4 cases (26.7%), invalid in 5 cases (33.3%), the total effective rate was 66.7%;Main adverse reactions during the treatment for bone marrow suppression and infection. Conclusion Application of fluorine dara marina combined cyclophosphamide scheme for the treatment of chronic lymphocytic leukemia has a remarkable clinical curative effect, because of its less side effects and good safety, is currently the preferred scheme in patients with chronic lymphocytic leukemia.
展开▼
